Small Cohort 2 sub-trial to obtain exploratory data on the expanded dose response of IMU-838.
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Vidofludimus calcium (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Immunic
Most Recent Events
- 26 Mar 2021 According to an Immunic media release, An unblinded interim analysis of selected MRI data is planned after all Cohort 2 patients have completed week 12 MRI assessments. company expects this data to be available at the end of March or in early April 2021.
- 15 Nov 2020 New trial record
- 05 Nov 2020 According to an Immunic media release, the still-active sites of the phase 2 trial of IMU-838 in RRMS continue to be used and, as a result,this assessment can be executed in an accelerated fashion.It is expected to provide additional data to address any potential regulatory requests in the context of the design of a phase 3 program. Management believes that this strategy will enable risk reduction for end-of-phase 2 discussions with regulatory agencies.